Corvus Pharmaceuticals (CRVS) Change in Accured Expenses (2015 - 2026)

Corvus Pharmaceuticals' Change in Accured Expenses history runs 12 years deep, the most recent figure standing at $499000.0 for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 241.78% year-over-year to $499000.0 in Q1 2026; TTM through Mar 2026 was $3.1 million, a 1657.0% increase from a year earlier, with the FY2025 full-year figure at $2.8 million, up 1226.94% from the prior year.
• Change in Accured Expenses retreated to $499000.0 in Q1 2026 per CRVS's latest filing, from $765000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.2 million in Q3 2022 and bottomed at -$1.9 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is $101000.0 (2024), against an average of -$5647.1.
• Across the five-year window, Change in Accured Expenses tumbled 481.53% in 2022 and soared 895.51% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at -$1.0 million in 2022, then surged by 42.37% to -$589000.0 in 2023, then grew by 16.81% to -$490000.0 in 2024, then surged by 256.12% to $765000.0 in 2025, then plunged by 34.77% to $499000.0 in 2026.
• Per Business Quant, the three latest CRVS Change in Accured Expenses figures stand at $499000.0 (Q1 2026), $765000.0 (Q4 2025), and $708000.0 (Q3 2025).